Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/10/2025

Aprepitant Use in Antiemetic Therapy

Introduction to Aprepitant

  • The National Comprehensive Cancer Network recommends aprepitant as part of a multimodal approach for preventing chemotherapy-induced nausea and vomiting, due to its ability to occupy NK1 receptors in the central nervous system, providing a different and complementary mechanism of action compared to other antiemetics 1

Compatibility with Other Antiemetics

  • Aprepitant can be safely combined with 5-HT3 receptor antagonists like ondansetron and has been shown to augment their antiemetic activity, with clinical studies demonstrating that aprepitant regimens including ondansetron are more effective than ondansetron alone for preventing both acute and delayed emesis 1, 2, 3
  • Aprepitant can be used alongside haloperidol as part of a multimodal approach for breakthrough emesis treatment, and metoclopramide and dimenhydrinate can be incorporated with aprepitant for managing breakthrough nausea and vomiting 4, 5, 6

Dosing Considerations

  • Standard oral aprepitant dosing for chemotherapy-induced nausea and vomiting is 125 mg on day 1, followed by 80 mg on days 2 and 3, according to the National Comprehensive Cancer Network guidelines 1, 2
  • When using aprepitant with dexamethasone, the dexamethasone dose should be reduced due to drug interactions 3

Drug Interactions

  • Aprepitant is a substrate, moderate inhibitor, and moderate inducer of CYP3A4, and also induces CYP2C9, with potential for drug interactions, although combinations with ondansetron, metoclopramide, dimenhydrinate, and haloperidol are not contraindicated 3, 7
  • Contraindicated combinations include pimozide, terfenadine, astemizole, and cisapride due to risk of serious reactions 3, 8

Clinical Efficacy

  • Aprepitant is particularly effective for preventing delayed emesis (25-120 hours after chemotherapy) compared to other antiemetics, with significant improvement in complete response rates when combined with standard antiemetic therapy (5-HT3 antagonist plus dexamethasone) 1, 2, 9

Important Considerations

  • For breakthrough nausea and vomiting, the general principle is to add agents from different drug classes, which supports combining aprepitant with other antiemetics, and preventing nausea and vomiting is generally more effective than treating established symptoms, so prophylactic use of aprepitant is recommended when indicated 4, 5, 6

REFERENCES

1

antiemesis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

2

antiemesis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

3

antiemesis. clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2009

4

antiemesis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

5

antiemesis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

6

antiemesis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

7

antiemesis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

8

antiemesis. clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2009

9

antiemesis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012